TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ertugliflozin on Cardiac Function in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2D taking oral antidiabetic medications (metformin and/or DPP4 inhibitors) except SGLT2 inhibitors for at least 12 weeks without a dose adjustment before enrollment.~* eGFR ≥ 45 mL/min/1.73 m2.~* Stage B HF identified on the basis of either structural or functional markers.~Exclusion Criteria:~* Type 1 diabetes mellitus~* At the time of screening age \<20 years~* HbA1c \<7% or HbA1c \>9.5% at Screening~* FPG \>15 mmol/L (270 mg/dL) measured by the laboratory at Screening (Visit 1), and confirmed (\>15 mmol/L \[\>270 mg/dL\]) by a repeat test before randomization~* Treated with insulin and/or GLP-1R agonist within 12 weeks preceding the Screening Visit.~* Women of childbearing potential with no effective contraceptive method~* History of gastric surgery including history of gastric banding within 3 years before the Screening Visit~* History of diabetic ketoacidosis or nonketotic hyperosmolar coma prior to the Screening Visit~* Mean blood pressure after 3 separate measurements \>180 mmHg in systolic blood pressure (SBP) or \>95 mmHg in diastolic blood pressure (DBP)~* Patients with current or prior symptoms of HF.~* Patients with severe anemia, severe respiratory, hepatic, neurological, psychiatric disorders or active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult~* Aspartate aminotransferase and/or alanine aminotransferase: \>3 times the upper limit of the normal laboratory range (ULN)~* Total bilirubin: \>1.5 times ULN (except in case of Gilbert's syndrome)~* Use of systemic glucocorticoids (excluding topical or ophthalmic, application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit~* Patient who has taken other investigational drugs or prohibited therapy for this study within 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin (Type: EXPERIMENTAL): Ertugliflozin 5 mg in addition to their preexisting metformin and/or DPP4 inhibitor
- Control group (Type: PLACEBO_COMPARATOR): Placebo in addition to their preexisting metformin and/or DPP4 inhibitor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching to Duloxetine in Patients With Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients aged 18 years or older who meet criteria for Major Depressive Disorder (MDD).~* Currently receiving a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) class of antidepressant for at least a month for the treatment of depression.~* Females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopause) to test negative for pregnancy based on a urine pregnancy test and to agree to use a reliable method of birth control.~Exclusion Criteria:~* Women who are pregnant or plan to be pregnant or are breastfeeding.~* To have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication.~* Diagnosed with treatment resistant depression.~* History of bipolar disorder, schizophrenia, or other psychotic disorders.~* To have previously taken duloxetine that didn't work.~* Judged to be at serious suicidal risk in the opinion of the investigator and/or score \>=3 on Item 3 (suicide) of the 17-Item Hamilton Depression Rating Scale (HAMD-17) at screening (Visit 1) or baseline (Visit 2).~* A serious medical illness that may need treatment during the study.~* Taking certain medications that are not allowed in this study.~* To have a history of alcohol and/or drug abuse or dependence within the past year.~* To have uncontrolled narrow-angle glaucoma.~* To have allergic reactions to many medicines.~* To have undergone shock therapy (Electroconvulsive Therapy) or magnet treatment (Transcranial Magnetic Stimulation) within the past year.~* To initiate talk therapy (psychotherapy) just before or during the study.~* To have chronic pain and you have been taking medicine for it for the last 6 months.~* To have certain liver diseases.~* To have kidney disease or undergoing dialysis.~* Abnormal thyroid stimulating hormone (TSH) concentration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Not currently on drug therapy for type 2 diabetes~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* Pregnancy or lactation~* Type 1 diabetes~* Evidence of serious diabetic complications~* Evidence of serious cardiovascular conditions~* Laboratory value abnormalities as defined by the protocol~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Preoperative N1539 in Colorectal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily provide written informed consent.~* Be planned to undergo primary (no repeat procedures) open or laparoscopic colorectal surgery (laparoscopic expected to require a ≥ 5 cm incision) with bowel resection and/or anastomosis.~* ASA physical status category 1, 2, or 3.~* Female subjects not pregnant or planning/attempting to become pregnant, not lactating; or commits to the use of an acceptable form of birth control for the duration of the study.~* Have a body mass index \<40 kg/m\^2~Exclusion Criteria:~* Have a known allergy or hypersensitivity to any study treatment.~* Planned surgical procedure includes a resection beyond the peritoneal reflection, is related to an acute bout of diverticulitis, or is associated with an emergency procedure.~* Have a history of myocardial infarction within the preceding 12 months.~* Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant condition that would preclude participation.~* Have active or recent (within 6 months) gastrointestinal ulceration or bleeding, with exception of events related to an ulcerative colitis diagnosis.~* Have a known bleeding disorder which may be worsened with the administration of an NSAID.~* Be currently receiving treatment with oral meloxicam (Mobic®) or another NSAID within 48 hours prior to surgery.~* Have previously received N1539/IV meloxicam or received any investigational product within 30 days before dosing with study medication.~* Have undergone or be expected to undergo radiation therapy, chemotherapy, or other biological therapy for cancer treatment, within 60 days prior to screening through last follow-up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- N1539 30 mg (Type: EXPERIMENTAL): N1539 (meloxicam injection for IV use) 30 mg every 24 hours
- IV Placebo (Type: PLACEBO_COMPARATOR): IV Placebo every 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older.~* Patients diagnosed with type 1 or 2 diabetes mellitus.~* Patients diagnosed with DMO with central involvement (defined as the area of the centre subfield of OCT) treated with intravitreal aflibercept (in accordance with routine practice).~* Patients for whom the decision to initiate treatment with intravitreal aflibercept was made as per the investigator's routine treatment practice and prior to study inclusion.~* Patients must provide written informed consent.~Exclusion Criteria:~* Patients under the age of 18.~* Patients with contraindications as listed in the SmPC for intravitreal aflibercept.~* Patients with pre-planned cataract surgery during the observational period.~* Patients previously treated with intravitreal anti-VEGF within 28 days.~* Patients currently or previously treated with systemic anti-VEGF.~* Patients previously treated with intravitreal fluocinolone acetonide steroid.~* Patients participating in an investigational programme with interventions outside of routine clinical practice.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 / Anti-VEGF treatment naïve patients (Type: None): Anti-VEGF treatment of naïve patients (who have not received any previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the United Kingdom.
- Cohort 2 / Anti-VEGF treatment non-naïve patients (Type: None): Anti-VEGF treatment of non-naïve patients (who have received previous anti-VEGF treatment) with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.
- Cohort 3 / Total study population (Type: None): Anti-VEGF treatment naïve patients and anti-VEGF treatment non-naïve patients with visual impairment due to diabetic macular oedema (DMO) in routine clinical practice in the UK.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (VKC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* At least the two following signs, in at least one eye\* (the same eye should fulfill both criteria):~  * Presence of giant papillae with a diameter ≥ 1 mm on the upper tarsal conjunctiva AND~ * Superficial keratitis~* At least two of the following ocular symptoms with a score \> 2 in at least one eye\*: burning/stinging, tearing, itching, pain, sticky eyelids, foreign body sensation, mucus discharge, and photophobia.~* Hyperemia score equal to or greater than 2.~Exclusion Criteria:~* Concomitant corneal ulcer of infectious origin.~* Active ocular herpes~* Disease that could possibly interfere with the interpretation of the study results: active uveitis (defined by Tyndall score \> 0), previous history of ocular hypertension or glaucoma, or condition incompatible with the frequent assessments needed by the study.~* Active herpes.~* History of malignancy or a recurrence in the last 5 years.~* Abnormality of nasolacrimal drainage apparatus.~* Concomitant disease not stabilized within 1 month before Screening Visit (e.g. diabetes with glycemia out of range, trouble with thyroid secretions, etc.) or judged by the investigator to be incompatible with the study (e.g. current systemic infections), or condition incompatible with the frequent assessments needed by the study.~* Known hypersensitivity to one of the components of the investigational medicinal products (IMP) or test products.~* Severe systemic allergy requiring systemic treatment at study entry.~* Female of childbearing potential.~* History of drug or alcohol addiction (\> 50g/day, 5 glasses alcohol/day).

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NOVA22007 0.05% (Type: EXPERIMENTAL): four times daily
- NOVA22007 0.1% (Type: EXPERIMENTAL): four times daily
- Vehicle (Type: SHAM_COMPARATOR): administered four times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese men and women aged 20 years or older~* Patients diagnosed as having NVG (neovascular glaucoma) with neovascularization in the anterior segment (both iris and anterior chamber angle)~* Patients with IOP (intraocular pressure) higher than 25 mmHg in the study eye due to anterior segment (both iris and anterior chamber angle) neovascularization~Exclusion Criteria:~* Patients with angle-closure due to conditions other than NVG or complete angle-closure due to NVG~* Patients with a known or suspected ocular or peri-ocular infection~* Patients with severe intraocular inflammation in the study eye~* Women who are pregnant, suspected of being pregnant or lactating~* Patients with known allergy to aflibercept

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVG patients (Type: EXPERIMENTAL): Japanese patients with neovascular glaucoma

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Age over 1 month and under 17 years~2. Confirmed diagnosis of COVID-19 infection with the results of real-time PCR~3. That they agreed to participate in the study.~4. That the patient tolerates the enteral route~Exclusion criteria~1. Have received vitamin D in the four weeks prior to hospitalization.

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- cholecalciferol (Vitamin D) (Type: EXPERIMENTAL): Children under 12 months they will be given 1000U and in children over 12 months they will be given 2000U every 24 hours orally during hospitalization
- Control (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent must be obtained before any assessment is performed~2. Male or female adults aged 18-65 years~3. Diagnosed with COPD according to GOLD 2016 (The ratio of post-bronchodilator forced expiratory volume in 1 second (FEV1) to force vital capacity (FVC)\<0.70 with the use of salbutamol 400ug)~4. Moderate to very severe airflow limitation (post-bronchodilator FEV1 \< 80% of the predicted normal value)~5. A documented history of at least 2 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticoids and/or antibiotics, or at least 1 exacerbation in the previous 12 months that requires hospitalization.~6. In the stable stage of COPD~Exclusion Criteria:~1. Patients who have clinically significant and chronic hepatic, renal, cardiovascular and gastrointestinal abnormalities or malignant tumor (except for lung cancer) which could interfere with the assessment of the efficacy and safety of the study treatment~2. Patients who are in critical conditions~3. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids or an acute exacerbation of any other diseases in the 4 weeks prior to screening~4. Patients with concomitant pulmonary disease (including but not limited to bronchiectasis, interstitial lung disease, asthma)~5. Patients who are highly likely to be lost during the 3-month treatment and the 1-year follow up~6. Pregnant or nursing (lactating) women~7. Patients who have been vaccinated against influenza in the current year, or against Streptococcus pneumoniae within five years, or have vaccination contraindications~8. Patients who are allergic to amikacin or other aminoglycosides~9. Patients who have participated in any interventional clinical trials in the three months prior to screening~10. Patients with mental diseases or cognitive disorders which could interfere with treatment and follow-up

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- oral probiotics (Type: EXPERIMENTAL): None
- aerosol inhaled amikacin (Type: EXPERIMENTAL): None
- combined vaccination (Type: EXPERIMENTAL): None
- conventional therapy (blank control) (Type: NO_INTERVENTION): According to the subjects' personal characteristics and guidance of The Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2017, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled glucocorticoids and long term oxygen therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-small cell lung cancer~  * Locally advanced (stage III) disease~ * Unresectable disease~* Candidate for concurrent definitive chemotherapy and thoracic radiotherapy, as determined by the treating physician~* No malignant pleural effusion~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Bilirubin ≤ 1.5 mg/dL~* AST or ALT ≤ 2 times upper limit of normal (ULN)~* Creatinine ≤ 1.5 times ULN~* FEV_1 \> 600 cc~* Not pregnant or nursing~* Negative pregnancy test~* No weight loss \> 10% within the past 6 months~* No known HIV disease~PRIOR CONCURRENT THERAPY:~* No prior thoracic radiotherapy~* No prior HIV protease inhibitors~* More than 5 years since prior chemotherapy~* At least 3 weeks since prior exploratory thoracotomy~* No concurrent medications that would preclude nelfinavir administration, including any of the following:~  * Amiodarone~ * Quinidine~ * Rifampin~ * Dihydroergotamine~ * Ergonovine~ * Ergotamine~ * Methylergonovine~ * Hypericum perforatum (St. John's wort)~ * Lovastatin~ * Simvastatin~ * Pimozide~ * Midazolam~ * Triazolam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): Nelfinavir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male, 18 to 60 years old~* Body mass index (BMI) ≥30 kg/m2 and ≤45 kg/m2 for subjects with uncomplicated obesity, or BMI ≥27 kg/m2 and ≤45 kg/m2 for subjects with dyslipidemia and/or controlled hypertension~Exclusion Criteria:~* History of type 1 or type 2 diabetes mellitus diagnosis~* Myocardial infarction within 6 months prior to screening~* Angina pectoris Grade III or IV as per the Canadian Cardiovascular Society grading scheme~* Clinical history of large vessel cortical strokes, including ischemic and hemorrhagic strokes (i.e., transient ischemic attack is not exclusionary)~* History (within the last 20 years) of seizures, cranial trauma, bulimia, anorexia nervosa, or other conditions that predispose subjects to seizures~* Past or planned surgical or device intervention (e.g., gastric banding) for obesity~* Chronic use or positive screen for opioids~* Regular use of tobacco products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- NB + CLI (Type: EXPERIMENTAL): Naltrexone SR 32 mg/Bupropion SR 360 mg/day (NB) with comprehensive lifestyle intervention (CLI)
- Usual Care (Type: OTHER): Usual Care (self-directed lifestyle intervention)~Usual Care: Usual Care was a self-directed lifestyle intervention in which subjects were given calorie targets, instructions to increase exercise, and a pamphlet about weight loss by study site staff.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete